Plus Therapeutics Inc (PSTV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Plus Therapeutics Inc (PSTV) has a cash flow conversion efficiency ratio of -1.306x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.13 Million) by net assets ($5.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PSTV market cap for the company's overall valuation and market capitalisation.
Plus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Plus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Plus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Plus Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Plus Therapeutics Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Good Way Technology Co Ltd
TWO:3272
|
0.056x |
|
Essen Tech Co. Ltd
KQ:043340
|
-0.038x |
|
Desoto Resources Ltd
AU:DES
|
-0.226x |
|
Infoline Tec Holdings Bhd
KLSE:0253
|
-0.190x |
|
Italian-Thai Development Public Company Limited
F:NYVF
|
0.490x |
|
Reka Industrial Oyj
HE:REKA
|
0.024x |
|
Mundoro Capital Inc
V:MUN
|
0.111x |
|
Armidian Karyatama Tbk PT
JK:ARMY
|
0.014x |
Annual Cash Flow Conversion Efficiency for Plus Therapeutics Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Plus Therapeutics Inc from 1998 to 2025. View today's stock price for Plus Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.00 Million | $-20.77 Million | -5.199x | -540.83% |
| 2024-12-31 | $-8.95 Million | $-10.55 Million | 1.179x | -87.63% |
| 2023-12-31 | $-1.35 Million | $-12.85 Million | 9.533x | +573.66% |
| 2022-12-31 | $6.45 Million | $-12.97 Million | -2.013x | -112.16% |
| 2021-12-31 | $10.84 Million | $-10.28 Million | -0.949x | +65.91% |
| 2020-12-31 | $3.03 Million | $-8.43 Million | -2.783x | +45.35% |
| 2019-12-31 | $1.16 Million | $-5.91 Million | -5.091x | -122.15% |
| 2018-12-31 | $5.22 Million | $-11.97 Million | -2.292x | -64.35% |
| 2017-12-31 | $13.00 Million | $-18.13 Million | -1.394x | +21.57% |
| 2016-12-31 | $10.99 Million | $-19.53 Million | -1.778x | -6.03% |
| 2015-12-31 | $12.21 Million | $-20.47 Million | -1.677x | -131.53% |
| 2014-12-31 | $-5.70 Million | $-30.33 Million | 5.319x | +148.20% |
| 2013-12-31 | $3.13 Million | $-34.56 Million | -11.035x | -121.27% |
| 2012-12-31 | $6.46 Million | $-32.19 Million | -4.987x | -40.43% |
| 2011-12-31 | $9.95 Million | $-35.32 Million | -3.551x | -244.59% |
| 2010-12-31 | $22.87 Million | $-23.57 Million | -1.031x | -115.84% |
| 2009-12-31 | $-3.66 Million | $-23.81 Million | 6.508x | +50.42% |
| 2008-12-31 | $-7.72 Million | $-33.39 Million | 4.327x | +35.59% |
| 2007-12-31 | $-9.40 Million | $-30.00 Million | 3.191x | +109.33% |
| 2006-12-31 | $-10.81 Million | $-16.48 Million | 1.524x | +762.42% |
| 2005-12-31 | $-6.23 Million | $-1.10 Million | 0.177x | +118.04% |
| 2004-12-31 | $12.83 Million | $-12.57 Million | -0.980x | -101.63% |
| 2003-12-31 | $14.91 Million | $-7.25 Million | -0.486x | -83.45% |
| 2002-12-31 | $26.00 Million | $-6.89 Million | -0.265x | -22.50% |
| 2001-12-31 | $38.49 Million | $-8.32 Million | -0.216x | -257.74% |
| 2000-12-31 | $49.34 Million | $-2.98 Million | -0.060x | -107.28% |
| 1999-12-31 | $-6.15 Million | $-5.11 Million | 0.831x | +105.89% |
| 1998-12-31 | $108.00K | $-1.52 Million | -14.102x | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric br… Read more